SAN DIEGO--(BUSINESS WIRE)--Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that the United States Patent and Trademark Office has issued a patent covering the composition of matter of RDEA806, the Company’s lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of patients with human immunodeficiency virus (HIV), and related analogs. U.S. Patent No. 7,435,752 was issued on October 14, 2008.
